Miniatura

Fitxers

870080.pdf (865.27 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2022-08-01

Llicència de publicació

(c) John Wiley & Sons, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/216934

Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/liv.15320

Resum

Background & aims: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods: Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results: Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. Conclusions: This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.

Matèries

Càncer de fetge, SARS-CoV-2, Assaigs clínics, Mortalitat

Matèries (anglès)

Liver cancer, SARS-CoV-2, Clinical trials, Mortality

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

MUÑOZ MARTÍNEZ, Sergio gabriel, SAPENA, Víctor, FORNER GONZÁLEZ, Alejandro, BRUIX TUDÓ, Jordi, SANDUZZI ZAMPARELLI, Marco, RÍOS, José, BOUATTOUR, Mohamed, EL KASSAS, Mohamed, LEAL, Cassia r.g., MOCAN, Tudor, NAULT, Jean-charles, ALVES, Rogerio c.p., REEVES, Helen l., DA FONSECA, Leonardo, GARCÍA JUÁREZ, Ignacio, PINATO, David j., VARELA, María, ALQAHTANI, Saleh a., ALVARES DA SILVA, Mario r., BANDI, Juan c., RIMASSA, Lorenza, LOZANO, Mar, GONZÁLEZ SANTIAGO, Jesús m., TACKE, Frank, SALA, Margarita, ANDERS, María, LACHENMAYER, Anja, PIÑERO, Federico, FRANÇA, Alex, GUARINO, María, ELVEVI, Alessandra, CABIBBO, Giuseppe, PECK-RADOSAVLJEVIC, Markus, ROJAS, Ángela, VERGARA, Mercedes, BRACONI, Chiara, PASCUAL, Sonia, PERELLÓ, Christie, MELLO, Vivianne, RODRÍGUEZ LOPE, Carlos, ACEVEDO, Juan, VILLANI, Rosanna, HOLLANDE, Clemence, VILGRAIN, Valérie, TAWHEED, Ahmed, FERGUSON THEODORO, Carmem, SPARCHEZ, Zeno, BLAISE, Lorraine, VIERA ALVES, Daniele e., WATSON, Robin, CARRILHO, Flair j., MOCTEZUMA VELÁZQUEZ, Carlos, D'ALESSIO, Antonio, IAVARONE, Massimo, REIG, María. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. _Liver International_. 2022. Vol. 42, núm. 8, pàgs. 1891-1901. [consulta: 22 de gener de 2026]. ISSN: 1478-3223. [Disponible a: https://hdl.handle.net/2445/216934]

Exportar metadades

JSON - METS

Compartir registre